Therapeutic Strategies for Disease-Modifying Therapy Management in Pregnant Women With Multiple Sclerosis: Relapse Risk and Clinical Implications
Highlights
- DMT management during pregnancy increases relapse risk in women with multiple sclerosis, especially with natalizumab interruption or prior fingolimod use.
- Anti-CD20 monoclonal antibody therapy administered prior to conception offers the greatest protection against pregnancy- and postpartum-related relapses.
- Natalizumab with short interruption is more effective than interferon β or glatiramer acetate for relapse prevention during pregnancy.
- Real-world registry data provide robust comparative effectiveness for DMT strategies across pregnancy stages.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.